CL2011002001A1 - Uso de 5-(2-{[6-(2-{[6-(2,2-difluoro-2-feniletoxi)exil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona en forma de recemato, estereoisomero o mezclas de esreoisomeros o una sal o solvato del mismo para preparar un medicamento para inhalacion util para normalizar la funcion pulmonar en un paciente humano. - Google Patents

Uso de 5-(2-{[6-(2-{[6-(2,2-difluoro-2-feniletoxi)exil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona en forma de recemato, estereoisomero o mezclas de esreoisomeros o una sal o solvato del mismo para preparar un medicamento para inhalacion util para normalizar la funcion pulmonar en un paciente humano.

Info

Publication number
CL2011002001A1
CL2011002001A1 CL2011002001A CL2011002001A CL2011002001A1 CL 2011002001 A1 CL2011002001 A1 CL 2011002001A1 CL 2011002001 A CL2011002001 A CL 2011002001A CL 2011002001 A CL2011002001 A CL 2011002001A CL 2011002001 A1 CL2011002001 A1 CL 2011002001A1
Authority
CL
Chile
Prior art keywords
phenylethoxy
hydroxyethyl
amino
exyl
spermatozoon
Prior art date
Application number
CL2011002001A
Other languages
English (en)
Spanish (es)
Inventor
Thorsten Massna Montejo Eric Ruf
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of CL2011002001A1 publication Critical patent/CL2011002001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
CL2011002001A 2009-02-18 2011-08-17 Uso de 5-(2-{[6-(2-{[6-(2,2-difluoro-2-feniletoxi)exil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona en forma de recemato, estereoisomero o mezclas de esreoisomeros o una sal o solvato del mismo para preparar un medicamento para inhalacion util para normalizar la funcion pulmonar en un paciente humano. CL2011002001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382020A EP2221055A1 (en) 2009-02-18 2009-02-18 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function

Publications (1)

Publication Number Publication Date
CL2011002001A1 true CL2011002001A1 (es) 2011-11-11

Family

ID=40833525

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002001A CL2011002001A1 (es) 2009-02-18 2011-08-17 Uso de 5-(2-{[6-(2-{[6-(2,2-difluoro-2-feniletoxi)exil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona en forma de recemato, estereoisomero o mezclas de esreoisomeros o una sal o solvato del mismo para preparar un medicamento para inhalacion util para normalizar la funcion pulmonar en un paciente humano.

Country Status (32)

Country Link
US (2) US20120029014A1 (OSRAM)
EP (2) EP2221055A1 (OSRAM)
JP (1) JP2012518019A (OSRAM)
KR (1) KR20110123742A (OSRAM)
CN (2) CN105326838A (OSRAM)
AR (1) AR075432A1 (OSRAM)
AU (1) AU2010214854A1 (OSRAM)
CA (1) CA2749059C (OSRAM)
CL (1) CL2011002001A1 (OSRAM)
CO (1) CO6361939A2 (OSRAM)
CY (1) CY1114484T1 (OSRAM)
DK (1) DK2398473T3 (OSRAM)
EA (1) EA022442B1 (OSRAM)
EC (1) ECSP11011336A (OSRAM)
ES (1) ES2430596T3 (OSRAM)
HR (1) HRP20130917T1 (OSRAM)
IL (1) IL213979A0 (OSRAM)
ME (1) ME01757B (OSRAM)
MX (1) MX2011008577A (OSRAM)
MY (1) MY155657A (OSRAM)
NZ (1) NZ593727A (OSRAM)
PE (1) PE20120419A1 (OSRAM)
PL (1) PL2398473T3 (OSRAM)
PT (1) PT2398473E (OSRAM)
RS (1) RS52951B (OSRAM)
SG (2) SG173091A1 (OSRAM)
SI (1) SI2398473T1 (OSRAM)
TW (2) TW201031408A (OSRAM)
UA (1) UA103370C2 (OSRAM)
UY (1) UY32414A (OSRAM)
WO (1) WO2010094483A1 (OSRAM)
ZA (1) ZA201104654B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2668941A1 (en) * 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
WO1992004928A2 (en) 1990-09-26 1992-04-02 Pharbita B.V. Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
RU2111020C1 (ru) 1992-12-18 1998-05-20 Шеринг Корпорейшн Ингалятор для порошковых лекарств
DE69634865D1 (de) 1995-04-14 2005-07-21 Smithkline Beecham Corp Dosierinhalator für Salmeterol
CA2378713C (en) 1995-06-21 2003-08-12 Asta Medica Aktiengesellschaft Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
FR2903168B1 (fr) * 2006-06-30 2008-08-22 Fayard Eliane Bruleur pour realiser la combustion de substances reputees difficilement combustibles
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico

Also Published As

Publication number Publication date
HRP20130917T1 (hr) 2013-11-08
CY1114484T1 (el) 2016-10-05
CN102325530A (zh) 2012-01-18
DK2398473T3 (da) 2013-10-21
EP2398473B1 (en) 2013-07-24
UY32414A (es) 2010-07-30
PL2398473T3 (pl) 2013-12-31
RS52951B (sr) 2014-02-28
US20120029014A1 (en) 2012-02-02
CA2749059A1 (en) 2010-08-26
HK1159990A1 (en) 2012-08-10
AU2010214854A1 (en) 2011-07-21
WO2010094483A1 (en) 2010-08-26
ES2430596T3 (es) 2013-11-21
CO6361939A2 (es) 2012-01-20
SG173091A1 (en) 2011-08-29
EA201101210A1 (ru) 2012-03-30
ME01757B (me) 2014-09-20
ZA201104654B (en) 2012-02-29
TW201442711A (zh) 2014-11-16
US20140343097A1 (en) 2014-11-20
MY155657A (en) 2015-11-13
MX2011008577A (es) 2011-09-06
EA022442B1 (ru) 2016-01-29
EP2398473A1 (en) 2011-12-28
JP2012518019A (ja) 2012-08-09
CN105326838A (zh) 2016-02-17
TW201031408A (en) 2010-09-01
EP2221055A1 (en) 2010-08-25
IL213979A0 (en) 2011-08-31
PT2398473E (pt) 2013-09-30
SI2398473T1 (sl) 2013-11-29
CA2749059C (en) 2017-08-01
PE20120419A1 (es) 2012-05-09
UA103370C2 (uk) 2013-10-10
SG2014012827A (en) 2014-04-28
ECSP11011336A (es) 2011-10-31
KR20110123742A (ko) 2011-11-15
NZ593727A (en) 2013-07-26
AR075432A1 (es) 2011-03-30

Similar Documents

Publication Publication Date Title
CL2011002001A1 (es) Uso de 5-(2-{[6-(2-{[6-(2,2-difluoro-2-feniletoxi)exil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona en forma de recemato, estereoisomero o mezclas de esreoisomeros o una sal o solvato del mismo para preparar un medicamento para inhalacion util para normalizar la funcion pulmonar en un paciente humano.
TR201818927T4 (tr) Kataterlerde İyileştirme
IL234508B (en) Inhalation of nitric oxide for treating respiratory diseases
CL2008000502A1 (es) Compuestos derivados de amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas; procedimiento de preparacion; medicamento; y uso del compuesto para el tratamiento y/o profilaxis de aldosteronismo, presion sanguinea alta, fallo cardiaco cronico, sec
AR093382A1 (es) Dispositivo de administracion de farmacos para el tratamiento de pacientes con enfermedades respiratorias
GB201318950D0 (en) Deployment Catheter
NZ716698A (en) Patient interface
IN2014DN07611A (OSRAM)
MX339614B (es) Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
BR112012017105A2 (pt) sistema para administrar um fluxo de gás de respiração para uma via aérea de um paciente, método de ventilar um paciente e sistema para ventilar um paciente
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
PE20141012A1 (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion
TR201008226A2 (tr) Kapsül içeren bir inhalasyon cihazı.
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX394276B (es) Inhalador de polvo seco y metodo de uso
CL2014000531A1 (es) Composicion farmaceutica para inhalacion que comprende 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)ona; inhalador que proporciona una dosis nominal menor que 5 µg; y su uso en el tratamiento de una enfermedad pulmonar o pastologia asociada con actividad de los receptores ß2 adrenergicos.
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
SMT201700098B (it) Aclidinio per l'uso nel miglioramento della qualità del sonno in pazienti con malattie respiratorie
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
AR100368A1 (es) Tratamiento de trastornos respiratorios
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood
TWD188084S (zh) 導管貼片
EP2442657A4 (en) USE OF R-BAMBUTEROL AS INHALED MEDICAMENT AND COMBINATION THERAPIES FOR THE TREATMENT OF RESPIRATORY DISEASES
BR112015018120A2 (pt) partículas cristalinas multicomponentes para terapia por inalação, composição farmacêutica, inalador de pó seco, inalador pressurizado dosimetrado, métodos de tratamento de uma doença ou distúrbio respiratório ou uma doença ou distúrbio pulmonar em um paciente, e, de preparação das partículas
CL2013003556A1 (es) Compuestos derivados de ftalazinona-pirrolo[3,2-d]pirimidin-carboxamida, inhibidoers de fosfodiesterasa tipo 4 y tipo 5; composcin farmaceutica que o comprende, combinacion fija, no fija y kit, uso del compuesto en la preparacion de un medicamento para trata enfermedaes de las vias respiratorias